Particle Engineering Lab, Process Research & Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Computational and Structural Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Mol Pharm. 2022 Sep 5;19(9):3304-3313. doi: 10.1021/acs.molpharmaceut.2c00456. Epub 2022 Aug 19.
Amorphous solid dispersions (ASDs) are a well-documented formulation approach to improve the rate and extent of dissolution for hydrophobic pharmaceuticals. However, weakly basic compounds can complicate standard approaches to ASDs due to pH-dependent solubility, resulting in uncontrolled drug release in gastric conditions and unstabilized supersaturated solutions prone to precipitation at neutral pH. This work examines the release mechanisms of amorphous dispersions containing model weakly basic pharmaceuticals posaconazole and lumefantrine from a basic poly(dimethylaminoethyl methacrylate) copolymer (Eudragit EPO) and compares their dissolution behavior with ASDs stabilized by acidic and neutral polymers to understand potential benefits to release from a basic polymeric stabilizer. It was found that dissolution of Eudragit EPO ASDs resulted in supersaturation under gastric conditions, which could be sustained upon adjustment to neutral pH. However, the dissolution behavior of Eudragit EPO ASDs was sensitive to the initial pH of the gastric media. For lumefantrine, elevated initial gastric pH resulted in precipitation of amorphous nanoparticles; for posaconazole, elevated gastric pH led to crystallization of the pharmaceutical from solution. This sensitivity to gastric pH was found to originate from the impact of Eudragit EPO on gastric pH and the solubility of each pharmaceutical in the first stage of dissolution. In total, these data illustrate benefits and liabilities for the use of Eudragit EPO for ASDs containing weak pharmaceutical bases to guide the design of robust pharmaceutical formulations.
无定形固体分散体(ASD)是一种经过充分证明的制剂方法,可提高疏水性药物的溶出速率和程度。然而,由于弱碱性化合物的 pH 依赖性溶解度,标准的 ASD 方法会变得复杂,导致在胃条件下药物释放不受控制,以及在中性 pH 下未稳定的过饱和溶液易于沉淀。这项工作研究了含有模型弱碱性药物泊沙康唑和盐酸阿莫地喹的 ASD 从碱性聚(二甲基氨基乙基甲基丙烯酸酯)共聚物(Eudragit EPO)中的释放机制,并将其与由酸性和中性聚合物稳定的 ASD 的溶解行为进行了比较,以了解从碱性聚合物稳定剂释放的潜在好处。结果发现,Eudragit EPO ASD 的溶解在胃条件下导致过饱和,在调整至中性 pH 时可以维持。然而,Eudragit EPO ASD 的溶解行为对胃介质的初始 pH 敏感。对于盐酸阿莫地喹,升高的初始胃 pH 导致无定形纳米颗粒沉淀;对于泊沙康唑,升高的胃 pH 导致药物从溶液中结晶。这种对胃 pH 的敏感性源于 Eudragit EPO 对胃 pH 的影响以及每种药物在溶解的第一阶段的溶解度。总的来说,这些数据说明了使用 Eudragit EPO 作为含有弱药物碱的 ASD 的优缺点,以指导稳健药物配方的设计。